Supply Agreements

The AMC Secretariat is proud to announce the first signature of AMC supply agreements. The following paragraphs are intended to provide specific information with regards to those supply agreements. The names of the participating companies are listed in alphabetical order.

Following the first call for AMC supply offers, published by UNICEF on 4 September 2009,

On 23 March 2010, GlaxoSmithKline (GSK) Biologicals signed a provisional supply agreement (PSA) with UNICEF. Under the PSA, GSK will supply 30 million doses annually (Annual Supply Commitment) from January 2012 for a period up to 10 years.
Consequently 15% of the AMC funds are allocated to this manufacturer according to the AMC terms and conditions. The tail price for this agreement is US$ 3.50. This agreement remains provisional, and vaccines will not be procured, until the candidate vaccine is deemed AMC eligible by the AMC Independent Assessment Committee.

On the same date, Pfizer Inc. signed a provisional supply agreement (PSA) with UNICEF. Under the PSA, Pfizer Inc. will supply 30 million doses (Annual Supply Commitment) annually from January 2013 for a period up to 10 years.

Consequently 15% of the AMC funds are allocated to this manufacturer according to the AMC terms and conditions. The tail price for this agreement is US$ 3.50. This agreement remains provisional, and vaccines will not be procured, until the candidate vaccine is deemed AMC eligible by the AMC Independent Assessment Committee.

In addition to those PSAs, GSK and Pfizer Inc. have agreed to provide in total 7.2 million doses, 24.2 million doses, and 20 million doses for the years 2010, 2011 and 2012 as part of the AMC Capacity Development Period. The capacity development period is defined as the period during which suppliers develop dedicated manufacturing capacity to serve GAVI Eligible Countries.

UNICEF has opted not to award the full quantities of the GAVI Strategic Demand Forecast for 2014 in response to this first tender. In order to incentivize manufacturers to accelerate the development of new vaccines, to contribute to the creation of a healthy market with multiple suppliers, and to enhance the possibility to access lower Tail Prices through future offers, quantities have been reserved for award at a later point in time.

70% of the AMC funds remains unallocated and will be available for successive rounds of calls for offers.